Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2026 08:30 ET | Source: CDT Equity Inc.

CDT Positions for Transformational Growth

CDT Positions for Transformational Growth
March 04, 2026 07:30 ET | Source: NervGen Pharma Corp.

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
March 04, 2026 04:00 ET | Source: Octopus AIM VCT 2 plc

Final Results

Octopus AIM VCT 2 plcFinal Results Octopus AIM VCT 2 plc today announces the final results for the year ended 30 November 2025. Octopus AIM VCT 2 plc (the ‘Company’) is a Venture Capital Trust (VCT)...
March 03, 2026 09:40 ET | Source: Research and Markets

7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Asthma - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The asthma market in the...
March 03, 2026 09:32 ET | Source: Research and Markets

Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Prostate Cancer - Competitive Landscape, 2026" report has been added to ResearchAndMarkets.com's offering.This "Prostate Cancer - Competitive...
March 03, 2026 04:00 ET | Source: Quell TX

Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval

London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients...
March 03, 2026 03:59 ET | Source: Quell TX

Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study

London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today...
March 02, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight

New York, USA, March 02, 2026 (GLOBE NEWSWIRE) -- Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum |...
March 02, 2026 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo...
March 02, 2026 07:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of...